Real-World Experience of Patients and Caregivers With Early-Line Treatment of Chronic Myeloid Leukemia in the US: A Retrospective 2-Year Social-Media Listening Analysis

Poster Presentation
© 2024 American Society of Hematology. All rights reserved.
Meeting: 2024 ASH® Annual Meeting
Indication: Chronic Myeloid Leukemia (CML)
Presenter: Gaurav Vadnerkar, PhD
Affiliation: Novartis Pharmaceuticals Corporation, East Hanover, NJ
Presentation Date: December 9, 2024
Abstract Number: 5192
Session: Session: 908. Outcomes Research: Myeloid Malignancies: Poster III
Related content: Chronic Myeloid Leukemia (CML)
Poster Presentation
Abstract Number: 5052
Presenter: Onyee Chan, MD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 9, 2024
Poster Presentation
Abstract Number: 3677
Presenter: Jennifer E Vaughn, MD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 8, 2024
Poster Presentation
Abstract Number: 4527
Presenter: Anchit Khanna, MMed.Sci., M.D., Ph.D.
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 9, 2024
Poster Presentation
Abstract Number: 3812
Presenter: Kejal Jadhav, B.Pharm, MS
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 8, 2024
Poster Presentation
Abstract Number: 1765
Presenter: Jorge E. Cortes, MD
Indication: Chronic Myeloid Leukemia (CML)
Date Presented: December 7, 2024

To access this content please accept the following declarations.

This content was selected by and is provided to you upon your unsolicited request courtesy of Novartis with permission of ASH®.